Literature DB >> 1309358

Ki-ras oncogene activation in preinvasive pancreatic cancer.

N R Lemoine1, S Jain, C M Hughes, S L Staddon, B Maillet, P A Hall, G Klöppel.   

Abstract

Activation of the Ki-ras oncogene by specific point mutations at codon 12 occurs at a remarkably high frequency in pancreatic ductal adenocarcinoma and is likely to be an important event in the pathogenesis of this cancer. To determine whether ras activation also occurs in noninvasive proliferative lesions of the pancreas, a series of cases of ductal papillary hyperplasia, intraductal papillary neoplasia, and intraduct extensions of ductal adenocarcinoma were examined for activating mutations of Ki-ras at codons 12, 13, and 61 using polymerase chain reaction amplification. Specific mutations at Ki-ras codon 12 were found in 5 of 6 cases (83%) of intraduct extensions of carcinomas and in 12 of 16 (75%) invasive carcinomas. In cases with both intraductal and invasive components, the same mutation was identified in each. No mutations were found in 5 intraductal papillary neoplasms and 9 cases of ductal papillary hyperplasia. The authors conclude that Ki-ras activation at codon 12 is important in the tumorigenesis of ductal adenocarcinoma of the pancreas but is not required in the pathogenesis of ductal papillary hyperplasia or intraductal papillary neoplasm.

Entities:  

Mesh:

Year:  1992        PMID: 1309358     DOI: 10.1016/0016-5085(92)91805-e

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  47 in total

1.  Detection of k-ras gene point mutation in fine needle aspiration and pancreatic juice by sequence special primer method and its clinical significance.

Authors:  Xun-Liang Liu; Cun-Cai Dai; Yi Miao; Jing-Hui Du; Zhao-Song Zhang; Shu-Zhen Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 3.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

4.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

5.  Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.

Authors:  V Stoll; V Calleja; G Vassaux; J Downward; N R Lemoine
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

6.  Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette.

Authors:  Wei Wang; Chun-You Wang; Ju-Hua Dong; Xiong Chen; Min Zhang; Gang Zhao
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

7.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.

Authors:  S T Dergham; M C Dugan; R Kucway; W Du; D S Kamarauskiene; V K Vaitkevicius; J D Crissman; F H Sarkar
Journal:  Int J Pancreatol       Date:  1997-04

8.  Detection of oncogenes in chronic pancreatitis.

Authors:  D Paramythiotis; J Kleeff; J Schmidt; M W Büchler; H Friess
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 9.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

10.  High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Authors:  Nir Lubezky; Menahem Ben-Haim; Sylvia Marmor; Eli Brazowsky; Gideon Rechavi; Joseph M Klausner; Yoram Cohen
Journal:  J Gastrointest Surg       Date:  2011-01-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.